Charles River Laboratories International (NYSE:CRL) Stock Rating Lowered by Wall Street Zen

Charles River Laboratories International (NYSE:CRL) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Friday.

A number of other equities analysts also recently issued reports on CRL. Bank of America upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective on the stock in a research note on Monday, December 15th. Robert W. Baird set a $224.00 target price on shares of Charles River Laboratories International in a research report on Friday, January 9th. TD Cowen reaffirmed a “buy” rating on shares of Charles River Laboratories International in a report on Thursday. Morgan Stanley set a $185.00 price target on Charles River Laboratories International in a research report on Monday, December 1st. Finally, Evercore ISI raised their price objective on Charles River Laboratories International from $250.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Ten equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $209.46.

Charles River Laboratories International Trading Down 1.9%

CRL opened at $219.77 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.37. The stock’s 50 day moving average price is $196.95 and its 200-day moving average price is $176.41. Charles River Laboratories International has a one year low of $91.86 and a one year high of $228.88. The stock has a market cap of $10.82 billion, a price-to-earnings ratio of -140.88, a P/E/G ratio of 6.56 and a beta of 1.61.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $2.32 by $0.11. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $990.43 million. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The company’s quarterly revenue was down .5% compared to the same quarter last year. During the same period last year, the company posted $2.59 earnings per share. On average, equities analysts forecast that Charles River Laboratories International will post 9.36 EPS for the current year.

Hedge Funds Weigh In On Charles River Laboratories International

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC grew its stake in Charles River Laboratories International by 31.8% during the 4th quarter. Farther Finance Advisors LLC now owns 853 shares of the medical research company’s stock valued at $170,000 after purchasing an additional 206 shares during the last quarter. Sage Mountain Advisors LLC lifted its holdings in shares of Charles River Laboratories International by 20.1% during the fourth quarter. Sage Mountain Advisors LLC now owns 1,865 shares of the medical research company’s stock worth $372,000 after purchasing an additional 312 shares during the period. Assetmark Inc. lifted its holdings in shares of Charles River Laboratories International by 17.9% during the fourth quarter. Assetmark Inc. now owns 43,809 shares of the medical research company’s stock worth $8,739,000 after purchasing an additional 6,666 shares during the period. Brown Miller Wealth Management LLC purchased a new stake in Charles River Laboratories International in the fourth quarter valued at approximately $238,000. Finally, Massachusetts Financial Services Co. MA acquired a new position in Charles River Laboratories International in the 4th quarter worth approximately $176,478,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.